SCANDION ONC. DK-0735 (F:8VY) — Market Cap & Net Worth

$140.86K USD  · €120.48K EUR  · Rank #31197

Market Cap & Net Worth: SCANDION ONC. DK-0735 (8VY)

SCANDION ONC. DK-0735 (F:8VY) has a market capitalization of $140.86K (€120.48K) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #31197 globally and #2793 in its home market, demonstrating a 50.00% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying SCANDION ONC. DK-0735's stock price €0.00 by its total outstanding shares 234762000 (234.76 Million).

SCANDION ONC. DK-0735 Market Cap History: 2021 to 2025

SCANDION ONC. DK-0735's market capitalization history from 2021 to 2025. Data shows change from $325.51 Million to $164.68K (-83.46% CAGR).

SCANDION ONC. DK-0735 Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how SCANDION ONC. DK-0735's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

No P/S ratio data available

Latest Price to Earnings (P/E) Ratio

No P/E ratio data available

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
No financial ratio data available

Competitor Companies of 8VY by Market Capitalization

Companies near SCANDION ONC. DK-0735 in the global market cap rankings as of June 19, 2026.

Key companies related to SCANDION ONC. DK-0735 by market ranking:

  • Metrics in Balance NV (PA:MLMIB): Ranked #31188 globally with a market cap of $144.89K USD ( €123.93K EUR).
  • Tasty Plc (LSE:TAST): Ranked #31189 globally with a market cap of $144.44K USD ( GBX1.19 Billion GBX).
  • LEPU MED.T.B. SP.GDR O.N. (F:07Z0): Ranked #31198 globally with a market cap of $140.36K USD ( €120.05K EUR).
  • LANEBURY GROWTH CAP. (F:L01): Ranked #31199 globally with a market cap of $138.76K USD ( €118.69K EUR).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#31188 Metrics in Balance NV PA:MLMIB $144.89K €0.03
#31189 Tasty Plc LSE:TAST $144.44K GBX0.53
#31198 LEPU MED.T.B. SP.GDR O.N. F:07Z0 $140.36K €13.20
#31199 LANEBURY GROWTH CAP. F:L01 $138.76K €0.01

SCANDION ONC. DK-0735 Historical Marketcap From 2021 to 2025

Between 2021 and today, SCANDION ONC. DK-0735's market cap moved from $325.51 Million to $ 164.68K, with a yearly change of -83.46%.

Year Market Cap Change (%)
2025 €164.68K -90.91%
2024 €1.81 Million -97.93%
2023 €87.42 Million +61.68%
2022 €54.07 Million -83.39%
2021 €325.51 Million --

End of Day Market Cap According to Different Sources

On Jun 19th, 2026 the market cap of SCANDION ONC. DK-0735 was reported to be:

Source Market Cap
Yahoo Finance $140.86K USD
MoneyControl $140.86K USD
MarketWatch $140.86K USD
marketcap.company $140.86K USD
Reuters $140.86K USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About SCANDION ONC. DK-0735

F:8VY Germany
Market Cap
$164.68K
€140.86K EUR
Market Cap Rank
#31197 Global
#2793 in Germany
Share Price
€0.00
Change (1 day)
-14.29%
52-Week Range
€0.00 - €0.00
All Time High
€2.18
About

Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for tr… Read more